Madrid

INTEROVIC Unveils Exclusive Lamb&Goat From Europe in Saudi Arabia

Retrieved on: 
Monday, September 11, 2023

The Interprofessional Organization for Sheep and Goat Meat in Spain, INTEROVIC, in collaboration with the Hungarian Sheep Meat Producers Organization, is proud to introduce the Exclusive Lamb&Goat from Europe program.

Key Points: 
  • The Interprofessional Organization for Sheep and Goat Meat in Spain, INTEROVIC, in collaboration with the Hungarian Sheep Meat Producers Organization, is proud to introduce the Exclusive Lamb&Goat from Europe program.
  • The event, attended by press representatives from the United Arab Emirates, Saudi Arabia, Japan, Hong Kong, and Spain, provided a platform for INTEROVIC members to elucidate the campaign's objectives.
  • Tomás Rodríguez Serrano, Director of INTEROVIC, commenced the event by illuminating the current status of the European sheep and goat sector.
  • For more information about the Exclusive Lamb&Goat program and its alignment with Saudi Vision 2030, please visit https://exclusivelambandgoat.eu/ .

I've spent 40 years studying Antarctica. The frozen continent has never needed our help more

Retrieved on: 
Tuesday, August 22, 2023

Right now, Antarctica’s climate and ecosystems are experiencing disturbing changes.

Key Points: 
  • Right now, Antarctica’s climate and ecosystems are experiencing disturbing changes.
  • A crucial ocean current is slowing down, and glaciers and ice shelves are disintegrating.
  • Some 22 of those were spent at the federal government’s Australian Antarctic Division; my final day there was last Thursday.
  • Read more:
    Antarctic alarm bells: observations reveal deep ocean currents are slowing earlier than predicted

Crucial to life as we know it

    • Without the buttressing of the ice shelves, glaciers flow faster to the sea.
    • In East Antarctica, lesser-known ice shelves have collapsed and glaciers are shrinking, adding to sea-level rise.
    • Scientific research is crucial in the face of these threats, to help better understand these changes now and over the longer term, and to feed into policy interventions.
    • Surprisingly a budget shortfall appears to be inadvertently curtailing plans for science this summer, according to the Guardian Australia.
    • In July, the ABC reported the Antarctic Division told staff A$25 million in budget savings was needed this financial year.
    • Efforts to reduce albatross bycatch in longline fishing were also led by Antarctic Division scientists.

Cleaning up the mess in Antarctica


    The story of Antarctica serves as a compelling reminder humanity must end our reliance on fossil fuels. We must also do a far better job of environmental stewardship – including paying for the scientific research so urgently needed. Failing to fully support vital Antarctic science in a rapidly unfolding climate emergency, in my view, is unwise.

The TYR Wodapalooza and Samsung Electronics America Announce Partnership Around the New Galaxy Watch5 Series

Retrieved on: 
Monday, October 10, 2022

MIAMI, Oct. 10, 2022 /PRNewswire/ -- The TYR Wodapalooza ("WZA") and Samsung Electronics America just announced an exciting collaboration around the upcoming WZA competitive event season, starting with the online challenge and qualifier and culminating in Miami this January. The partnership centers around Samsung's new Galaxy Watch5 and Watch5 Pro and its diverse and complimentary functionality for both recreational and competitive athletes.

Key Points: 
  • The partnership centers around Samsung's new Galaxy Watch5 and Watch5 Pro and its diverse and complimentary functionality for both recreational and competitive athletes.
  • The Galaxy Watch5 has been improved compared to past iterations, the watch itself is simply more durable.
  • The TYR Wodapalooza, the event owned and operated by Loud And Live, is the perfect platform for Samsung to connect with the passionate CrossFit community.
  • We can't wait to showcase the Galaxy Watch5 Series, and how together with Samsung, we'll continue elevating the event," said Marco Sagrera, Chief Strategy Officer of Loud And Live.

Leuko Raises $5 Million Series A to Validate and Bring to Market Its Noninvasive White Blood Cell Monitoring Technology for Cancer Patients

Retrieved on: 
Friday, September 23, 2022

Leuko, an MIT startup developing PointCheckTM, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, today announced a first closing of $5 million for their Series A round.

Key Points: 
  • Leuko, an MIT startup developing PointCheckTM, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, today announced a first closing of $5 million for their Series A round.
  • Leuko will also continue to pursue its go-to-market and partnership activities with healthcare providers, medical device distributors and pharmaceutical companies.
  • Low WBC levels is one of the most common as well as most devastating and costliest side effects of cancer chemotherapy.
  • With Leuko, patients simply place their finger onto an internet connected PointCheckTM device for just 1 minute a day.

TYR Becomes Title Sponsor of the Wodapalooza Fitness Festival

Retrieved on: 
Thursday, July 7, 2022

MIAMI, July 7, 2022 /PRNewswire/ -- Today, leading performance brand, TYR Sport, was announced as the first ever Title Sponsor of the internationally renowned Wodapalooza Fitness Festival ("WZA"). The four-day CrossFit-inspired festival and competition takes place annually in January in Miami, Florida. Seeking to bolster the CrossFit community and sport, TYR will seek to infuse its own brand and life into the decade-old event, all in an effort to add value to the CrossFit community and its athletes.

Key Points: 
  • MIAMI, July 7, 2022 /PRNewswire/ -- Today, leading performance brand, TYR Sport, was announced as the first ever Title Sponsor of the internationally renowned Wodapalooza Fitness Festival ("WZA").
  • "As the title sponsor of Wodapalooza, TYR will be able to take an athlete-first approach to interacting with the CrossFit community.
  • In 2023, the TYR Wodapalooza Fitness Festival will once again take place at Bayfront Park in Downtown Miami and will feature four days of competition as the focal point of its weekend-long festival.
  • While nothing beats experiencing this historic event in person, the TYR Wodapalooza Fitness Festival will be streamed globally and free, with more information coming soon.

Making Science Continues International Expansion With Two Acquisitions in Q1 2022

Retrieved on: 
Friday, February 11, 2022

The acquisitions are part of the expansion process that Making Science has been carrying out since 2020, both nationally and internationally.

Key Points: 
  • The acquisitions are part of the expansion process that Making Science has been carrying out since 2020, both nationally and internationally.
  • These acquisitions in the first-quarter of 2022 follow seven carried out in 2021 as part of the companys organic growth strategy.
  • The deals will see an additional 50 professionals incorporated into the Making Science workforce from Tre Kronor Media and 30 new professionals from ELLIOT.
  • The markets in which Making Science operates are digital advertising, data analytics, e-commerce and cloud, all of them with high growth rates.

Highlight Therapeutics: BO-112 published in JITC

Retrieved on: 
Thursday, December 2, 2021

MADRID, Spain, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and the Spanish research institute Cima Universidad de Navarra today announced that positive results from a pre-clinical study of intratumoral administration of BO-112 with a STING agonist have been published in the Journal for ImmunoTherapy of Cancer (JITC, Impact Factor 13.75). 1

Key Points: 
  • "These results, following the positive Phase 2 data on the combination of BO-112 and anti-PD1 therapies, are very encouraging," said Dr. Marisol Quintero, CEO of Highlight Therapeutics.
  • The main objective has been to achieve both local control of the disease and, more importantly, efficacy against distant tumor lesions.
  • The work published in the Journal for ImmunoTherapy of Cancer shows that co-injections of BO-112 and a STING agonist attain synergistic efficacy, enabling distant uninjected tumor lesions to be eradicated.
  • Conclusion Clinically feasible co-injections of BO-112 and a STING agonist attain synergistic efficacy able to eradicate distant untreated tumor lesions.

Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics

Retrieved on: 
Thursday, November 18, 2021

Biokit currently markets three commercial products that use antigens produced using Algenex technologies, including recombinant proteins for the detection of Herpes Simplex Virus (HSV) and Parvovirus.

Key Points: 
  • Biokit currently markets three commercial products that use antigens produced using Algenex technologies, including recombinant proteins for the detection of Herpes Simplex Virus (HSV) and Parvovirus.
  • Biokit is developing additional products, for which Algenex will receive royalties on net sales.
  • Claudia Jimnez, CEO of Algenex said We are pleased to continue our longstanding and successful relationship with Biokit, a world renowned IVD company.
  • We are pleased to renew this agreement and look forward to continuing to work with Algenex to deliver innovation and enhance patient care around the world.

Positive Phase 2b results in 2nd line melanoma

Retrieved on: 
Friday, November 12, 2021

MADRID, Spain, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced positive preliminary results of a Phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy. BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.

Key Points: 
  • BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.
  • "These are potentially game-changing results showing that BO-112 can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1," said Dr Carlos Paya, Executive Chairman of Highlight Therapeutics.
  • These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment.
  • With a median follow up of three months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 27% ORR and a 65% DCR, superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).

Positive Phase 2b results in 2nd line melanoma

Retrieved on: 
Friday, November 12, 2021

BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.

Key Points: 
  • BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.
  • "These are potentially game-changing results showing that BO-112 can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1," said Dr Carlos Paya, Executive Chairman of Highlight Therapeutics.
  • These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment.
  • With a median follow up of three months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 27% ORR and a 65% DCR, superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).